Skip to main content
. 2022 Jun 24;15(9):2146–2158. doi: 10.1111/cts.13348

TABLE 3.

Statistical comparison of pharmacokinetic exposure parameters after co‐administration of EDP‐305 with different probes

Treatment N Probe + EDP‐305 test N Probe alone reference Geo LSMean ratio (90% CI)
Geo LSMean Geo LSMean
EDP‐305 as perpetrator
Study 004 effect on midazolam
Cmax, ng/ml 24 9.41 24 7.51 1.25 (1.11, 1.41)
AUC0,inf, h ng/ml 24 32.22 24 20.73 1.55 (1.32, 1.83)
Study 004 effect on caffeine
Cmax, ng/ml 24 4718 24 4191 1.13 (1.04, 1.21)
AUC0,inf, h ng/ml 15 61,746 23 31,655 1.95 (1.61, 2.36)
Study 004 effect on rosuvastatin
Cmax, ng/ml 24 5.59 24 5.04 1.11 (0.94, 1.31)
AUC0,inf, h ng/ml 22 61.19 22 49.49 1.24 (1.03, 1.48)
Study 008 effect on ethinyl estradiol
Cmax, pg/ml 31 148 35 137 1.08 (0.99, 1.19)
AUC0,t, h pg/ml 31 1350 35 1250 1.08 (1.00, 1.16)
Study 008 effect on norelgestromin
Cmax, pg/ml 31 2470 35 2640 0.94 (0.86, 1.02)
AUC0,t, h pg/ml 31 25,600 35 25,900 0.99 (0.92, 1.05)
Study 008 effect on levonorgestrel
Cmax, pg/ml 31 3850 35 2990 1.29 (1.21, 1.38)
AUC0,t, h pg/ml 31 74,800 35 57,200 1.31 (1.23, 1.39)
Probe + EDP‐305 test N EDP‐305 alone reference
EDP‐305 as victim
Study 005 itraconazole effect
Cmax, ng/ml 21 50.48 24 31.25 1.62 (1.28, 2.04)
AUC0,inf, h ng/ml 18 1891.47 24 360.31 5.25 (4.26, 6.48)
Study 005 rifampin effect
Cmax, ng/ml 21 27.02 24 29.62 0.91 0.77, 1.08)
AUC0,inf, h ng/ml 19 137.92 24 393.59 0.35 (0.30, 0.41)
Study 007 fluconazole effect
Cmax, ng/ml 24 57.71 24 32.73 1.76 (1.56, 1.99)
AUC0,inf, h ng/ml 24 1537.60 24 408.40 3.77 (3.40, 4.17)
Study 007 quinidine effect
Cmax, ng/ml 24 31.78 24 31.64 1.00 (0.92, 1.10)
AUC0,inf, h ng/ml 24 367.17 24 353.24 1.04 (0.95, 1.14)

Abbreviations: AUC0,inf, area under the concentration curve from time 0 to infinity; CI, 90% confidence interval; Cmax, peak plasma concentration; Geo LSMean, geometric least square mean.